【正文】 rejection Negative immune response Immune tolerance Immunisuppressive agents CsA, Rapa, antiCD4 mAb, irradiation ? Graft rejection Regulatory CD4+CD25+Foxp3+T cells Effector T cells Zhang LJ J Cell Phy 2022 Liu GW Immunology 2022 Yi HF Exp Rev of CLin Immunol 2022 A % of CD4+ CD25+ /CD4+ cells ** 0 5 10 15 20 25 30 B Control CsA Spleen LNs Total cell no of CD4+ CD25+ cells (X106) * 0 1 2 3 Control CsA Spleen LNs CsA significantly decreased the percentages of CD4+CD25+Treg cells in spleens Wang HJ, Zhao L, Sun ZY, Sun LG, and Zhao Y. Transplantation 2022. C ** * * ** * 0 25 50 75 100 125 150 3 HTdR uptake (cpm103 ) 0 1 2 4 0 5 10 15 20 25 0 50 100 150 200 3 HTdR uptake (cpm103 ) 3 HTdR uptake (cpm103 ) 0 1 2 4 0 1 2 CD4+CD25+ cell No (X103) CD4+CD25+ cell No (X103) CD4+CD25+ cell No (X103) B A * * * Control CsA Control CsA Control CsA CsA significantly inhibited the function of CD4+CD25+Treg cells in mice Wang HJ, Zhao L, Sun ZY, Sun LG, and Zhao Y. Transplantation 2022. ConA MLRC57 MLRC3H control rapa 0 5 10 15 20 25 30 % of CD4+ cells *** B C 0 5 10 15 20 25 % of CD4+ CD25high cells in CD4+cells ** 0 1 2 3 4 % of CD4+ CD25 high cells A Qu Yanyan et al, Transpl Immunol 2022 Rapamycine relatively enhanced Treg cell levels in spleens 3HTdR uptake (cpm103 ) 3HTdR uptake (cpm103 ) 0 10 20 30 40 50 60 70 80 90 0 5 10 20 40 control rapamycin CD4+CD25 CD4+CD25+ cell No (X103) 0 20 40 60 80 100 120 0 5 10 20 CD4+CD25+ cell No (X103) A B B6 CD4+CD25+ : control rapatreated Sens. B6 T cells: + + + + Balb/c SPMs: + + + + 0 40 80 120 160 200 P＞ ** ** ear thickness change (um) C 24 hours ** ** ** ** ** ** ** ** * ** ** * Qu Yanyan et al, Transplant Immunol 2022 Rapamycine did not change the function of Treg cells CsA具有抑制調(diào)節(jié)性 T細(xì)胞的功能，而Rap則對(duì)調(diào)節(jié)性 T細(xì)胞無(wú)明顯影響。因此，在移植時(shí)，選擇 rap 作為藥物處理較合適。 對(duì)抗 CD4 抗體、電離輻射、阿斯匹林、MMF、 LEF等對(duì)調(diào)節(jié)性 T細(xì)胞的影響進(jìn)行了研究。 Yi HF et al Transpl (in revision) Zhang AJ et al J Mol Med (2022) Qu YY et al Radiation Res (in revision) Zhao Y. Exp Rev of Clin Immunol 2022 Ceng C Int Rev of Immunol 2022 Zhang LJ et al unpublished data B、 T淋巴細(xì)胞下調(diào)因子（ BTLA） F i l e: 06 03 2 1 10 2 . 00 2 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 66 .4 1 66 .4 1 5. 15 4. 33UR 17 .4 3 17 .4 3 16 9. 69 13 9. 16LL 11 .6 8 11 .6 8 5. 82 4. 69LR 4. 48 4. 48 12 6. 96 10 6. 07F i l e: 06 03 2 1 10 2 . 01 1 G at e: N o G at eG at ed Ev en t s : 36 16 T ot al Ev e nt s: 3 61 6Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 0. 64 0. 64 8. 86 6. 74UR 0. 55 0. 55 78 .3 6 66 .0 0LL 83 .1 3 83 .1 3 5. 49 4. 66LR 15 .6 8 15 .6 8 12 0. 48 10 2. 97F i l e: 06 03 2 1 10 2 . 00 3 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 71 .9 5 71 .9 5 5. 05 4. 24UR 15 .0 4 15 .0 4 12 8. 24 10 9. 53LL 9. 34 9. 34 5. 81 4. 73LR 3. 67 3. 67 10 1. 00 86 .2 2F i l e: 06 03 2 1 10 2 . 00 4 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 75 .2 3 75 .2 3 4. 45 3. 72UR 10 .5 6 10 .5 6 14 4. 74 12 1. 89LL 10 .0 6 10 .0 6 5. 42 4. 33LR 4. 15 4. 15 11 6. 61 98 .1 0F i l e: 06 03 2 1 10 2 . 00 5 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 42 .8 4 42 .8 4 4. 89 4. 04UR 13 .4 3 13 .4 3 14 1. 02 11 6. 17LL 41 .7 5 41 .7 5 3. 40 3. 03LR 1. 98 1. 98 96 .3 6 83 .6 8F i l e: 06 03 2 1 10 2 . 00 6 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 41 .6 3 41 .6 3 5. 40 4. 35UR 15 .0 3 15 .0 3 15 0. 51 12 7. 48LL 41 .1 7 41 .1 7 3. 55 3. 13LR 2. 17 2. 17 10 5. 35 90 .0 6F i l e: 06 03 2 1 10 2 . 00 7 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 42 .5 3 42 .5 3 5. 27 4. 25UR 13 .3 9 13 .3 9 15 1. 24 12 7. 30LL 41 .8 1 41 .8 1 3. 54 3. 13LR 2. 27 2. 27 10 1. 97 90 .0 9F i l e: 06 03 2 1 10 2 . 00 8 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 73 .7 8 73 .7 8 4. 21 3. 39UR 15 .6 0 15 .6 0 13 5. 77 11 3. 83LL 9. 74 9. 74 4. 09 3. 46LR 0. 88 0. 88 10 4. 33 87 .1 6F i l e: 06 03 2 1 10 2 . 00 9 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 70 .6 4 70 .6 4 4. 14 3. 36UR 18 .1 6 18 .1 6 13 8. 35 11 7. 79LL 10 .1 8 10 .1 8 3. 94 3. 41LR 1. 02 1. 02 11 9. 79 97 .2 5F i l e: 06 03 2 1 10 2 . 01 0 G at e: N o G at eG at ed Ev en t s : 10 00 0 T ot al Ev e nt s: 1 00 0 0Q ua d % G at ed % T ot al X M ea n X G eo M ea nUL 72 .5 7 72 .5 7 4. 33 3. 51UR 15 .9 1 15 .9 1 14 3. 67 12 2. 29LL 10 .4 0 10 .4 0 4. 08 3. 49LR 1. 12 1. 12 10 2. 64 9